Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Iron Sucrose Injection in Healthy Participants
NCT06674486Phase 1Completed
- Sponsor
- Sichuan Huiyu Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of iron sucrose in iron deficiency anemia (IDA) (2 arms), sponsored by Sichuan Huiyu Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration up to 36 hours and Area Under the Curve from time zero to the last measurable concentration up to 36 hours. Started Nov 2024; status: completed.
02
Drugs
iron sucrose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT06674486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06674486.